Invivyd Q3 2026 Earnings: PEMGARDA Revenue Rises 18% To $15.4 Million

Invivyd's Q3 2026 PEMGARDA net product revenue grew 18% to $15.4 million, while net loss widened to $33.5 million as VYD2311 trial and commercial costs rose. Cash was $126.4 million.

Invivyd Q3 2026 Earnings: PEMGARDA Revenue Rises 18% To $15.4 Million

Invivyd's Q3 2026 PEMGARDA net product revenue grew 18% to $15.4 million, while net loss widened to $33.5 million as VYD2311 trial and commercial costs rose. Cash was $126.4 million.

Ticker: IVVD

Invivyd, Inc. (IVVD), the New Haven, Connecticut maker of the COVID-19 monoclonal antibody PEMGARDA, reported third quarter 2026 results on 16 November. Sales grew on increased patient demand, but research and commercial costs roughly doubled as the company pushed its next antibody, VYD2311, through late-stage trials and toward a planned Biologics License Application under the FDA's Accelerated Approval Program.

The key numbers (quarter ended 30 September 2026, $ in thousands except per share)

Metric

This year

Last year

Change

Product revenue, net

$15,449

$13,129

+18%

Research and development

$18,736

$8,046

Selling, general and administrative

$30,349

$15,018

Loss from operations

$(34,679)

$(11,023)

Net loss

$(33,468)

$(10,470)

Net loss per share

$(0.10)

$(0.06)

Cash and cash equivalents

$126.4 million

The rise in R&D was mainly due to contract research costs for the DECLARATION and LIBERTY trials of VYD2311. SG&A rose on personnel, communications and commercial-related costs.

Pipeline and corporate

In September, Invivyd reported positive topline results from the LIBERTY Phase 3 trial, in which VYD2311 met all primary and secondary endpoints against an mRNA-based COVID-19 vaccine on safety and tolerability. The company said interim data from the DECLARATION Phase 3 trial, intended to support the planned BLA, were expected imminently following further discussions with the FDA. In October the company started FLINTLOCK, a Phase 2 trial in Long COVID and Post-Vaccination Syndrome, and presented VMS063, a measles antibody candidate.

In July, Invivyd received twelve months' notice of the termination of PEMGARDA's Emergency Use Authorization. Chairman Marc Elia was appointed Chief Executive Officer in September.

CFO Bill Duke said PEMGARDA's continued growth, despite declining COVID vaccine use and the coming end of its authorization, shows clear demand for monoclonal antibodies.

Nine months so far

Product revenue was $43,478 thousand against $36,219 thousand, and net loss was $(119,261) thousand against $(41,419) thousand.

Source: SEC Form 8-K Exhibit 99.1

STOCKS IN THIS ARTICLE

Comments